The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.




Funding of PBTCF 2020: PBTC-058 - $25,000

Amount
$25,000.00
Date
January 2020

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

Sydney Children's Hospital - $151,468

Amount
$151,468.00
Date
December 2019

Developing New Epigenetic Combination Treatments Against DIPG.

Oncoceutics ONC201 - $100,000

Amount
$100,000.00
Date
December 2019

Expansion of the ONC201 Compassionate Use.

University of Sydney - $100,000

Amount
$100,000.00
Date
November 2019

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an approach of radiosensitization for diffuse intrinsic pontine gliomas.

University of Michigan Hospitals - $157,856

Amount
$157,856.00
Date
November 2019

Therapeutic reversal of pre-natal pontine ID1 signaling in DIPG

Dayton Children's Hospital - $69,600

Amount
$69,600.00
Date
November 2019

Responses of distinct cell populations to PDGFRA inhibitors in diffuse intrinsic pontine glioma.

Institute of Cancer Research - $121,863

Amount
$121,863.00
Date
November 2019

Targeting Top3A-Amplified DIPG cells by Sirtuin inhibition.

Bambino Gesu Children's Hospital - $49,803

Amount
$49,803.00
Date
August 2019

Using imaging mass cytometry to identify next generation imaging biomarkers in PHGG and DIPG.

Telethon Kids Institute - $49,512

Amount
$49,512.00
Date
August 2019

Development of a new and effective therapy against Diffuse Intrinsic Pontine Glioma.

Oncoceutics ONC201 - Phase II - $83,333

Amount
$83,333.00
Date
May 2019

Expansion of the ONC201 Compassionate Use.

Funding of PBTCF 2019: PBTC-058 - $25,000

Amount
$25,000.00
Date
January 2019

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

Sydney Children’s Hospital - $175,089

Amount
$175,089.00
Date
November 2018

Polyamine Pathway Metabolism as a Novel Therapeutic Option for Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital - $540,742

Amount
$540,742.00
Date
November 2018

Expansion of the International DIPG Registry.

Bambino Gesú Children's Hospital - $99,382

Amount
$99,382.00
Date
November 2018

Investigating the Role of DIPG-Derived Exosomes in Tumor Growth and Invasion.

Ann and Robert H. Lurie Children's Hospital of Chicago - $35,000

Amount
$35,000.00
Date
November 2018

Credentialing an Improved DIPG Mouse Model.